Differential regulation patterns of the anti-CD20 antibodies obinutuzumab and rituximab in mantle cell lymphoma

British Journal of Haematology

Volumn 168, Issue 4, 2015, Pages 606-610

  Heinrich, Daniel A ^a,b   Weinkauf, Marc ^a,b   Hutter, Grit ^a,b   Zimmermann, Yvonne ^a,b   Jurinovic, Vindi ^c   Hiddemann, Wolfgang ^a,b   Dreyling, Martin ^a,b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

Author keywords

Anti CD20; Mantle cell lymphoma; Monoclonal antibodies; Obinutuzumab; Rituximab

Indexed keywords

BCL2 RELATED PROTEIN A1; DUAL SPECIFICITY PHOSPHATASE 2; EARLY GROWTH RESPONSE FACTOR 1; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN G ANTIBODY; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; OBINUTUZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; RITUXIMAB; SMALL INTERFERING RNA; SURVIVIN; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR SOX11; TRANSCRIPTOME; WNT3 PROTEIN; ANTINEOPLASTIC AGENT; CD20 ANTIGEN; MONOCLONAL ANTIBODY; TUMOR PROTEIN;

AP 1 GENE; ARTICLE; BCL2A1 GENE; BINDING COMPETITION; BIRC5 GENE; CANCER COMBINATION CHEMOTHERAPY; CCL3 GENE; CCL4 GENE; CELL KILLING; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG POTENTIATION; DUSP2 GENE; EGR1 GENE; GENE; GENE EXPRESSION REGULATION; GRANTA 519 CELL LINE; IN VITRO STUDY; INTRACELLULAR SIGNALING; JEKO 1 CELL LINE; MANTLE CELL LYMPHOMA; MANTLE CELL LYMPHOMA CELL; MONOTHERAPY; NFATC1 GENE; NFKBIE GENE; PI3K GENE; REC 1 CELL LINE; SOX11 GENE; WNT3 GENE; Z 138 CELL LINE; ANTIBODY SPECIFICITY; BIOSYNTHESIS; COMPARATIVE STUDY; DRUG EFFECTS; GENETICS; HUMAN; IMMUNOLOGY; LYMPHOMA, MANTLE-CELL; PATHOLOGY; TUMOR CELL LINE;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIBODY SPECIFICITY; ANTIGENS, CD20; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN VITRO TECHNIQUES; LYMPHOMA, MANTLE-CELL; NEOPLASM PROTEINS;

EID: 84922981579     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13132     Document Type: Article

References (10)

1. Chen, L., Wang, S., Zhou, Y., Wu, X., Entin, I., Epstein, J., Yaccoby, S., Xiong, W., Barlogie, B., Shaughnessy, J.D. Jr & Zhan, F. (2010) Identification of early growth response protein 1 (EGR-1) as a novel target for JUN-induced apoptosis in multiple myeloma. Blood, 115, 61-70.
2. Cittera, E., Leidi, M., Buracchi, C., Pasqualini, F., Sozzani, S., Vecchi, A., Waterfield, J.D., Introna, M. & Golay, J. (2007) The CCL3 family of chemokines and innate immunity cooperate in vivo in the eradication of an established lymphoma xenograft by rituximab. Journal of Immunology, 178, 6616-6623.
3. Dreyling, M. & Hiddemann, W. (2009) Current treatment standards and emerging strategies in mantle cell lymphoma. Hematology/The Education Program of the American Society of Hematology. American Society of Hematology. Education Program, 2009, 542-551.
4. Franke, A., Niederfellner, G.J., Klein, C. & Burtscher, H. (2011) Antibodies against CD20 or B-cell receptor induce similar transcription patterns in human lymphoma cell lines. PLoS ONE, 6, e16596.
5. Mossner, E., Brunker, P., Moser, S., Puntener, U., Schmidt, C., Herter, S., Grau, R., Gerdes, C., Nopora, A., van Puijenbroek, E., Ferrara, C., Sondermann, P., Jager, C., Strein, P., Fertig, G., Friess, T., Schull, C., Bauer, S., Dal Porto, J., Del Nagro, C., Dabbagh, K., Dyer, M.J., Poppema, S., Klein, C. & Umana, P. (2010) Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood, 115, 4393-4402.
6. Niederfellner, G., Lammens, A., Mundigl, O., Georges, G.J., Schaefer, W., Schwaiger, M., Franke, A., Wiechmann, K., Jenewein, S., Slootstra, J.W., Timmerman, P., Brannstrom, A., Lindstrom, F., Mossner, E., Umana, P., Hopfner, K.P. & Klein, C. (2011) Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies. Blood, 118, 358-367.
7. Rizzatti, E.G., Falcao, R.P., Panepucci, R.A., Proto-Siqueira, R., Anselmo-Lima, W.T., Okamoto, O.K. & Zago, M.A. (2005) Gene expression profiling of mantle cell lymphoma cells reveals aberrant expression of genes from the PI3K-AKT, WNT and TGFbeta signalling pathways. British Journal of Haematology, 130, 516-526.
8. Shaulian, E. & Karin, M. (2001) AP-1 in cell proliferation and survival. Oncogene, 20, 2390-2400.
9. Vogler, M. (2012) BCL2A1: the underdog in the BCL2 family. Cell Death and Differentiation, 19, 67-74.
10. Wagner, M., Schmelz, K., Dorken, B. & Tamm, I. (2008) Transcriptional regulation of human survivin by early growth response (Egr)-1 transcription factor. International Journal of Cancer, 122, 1278-1287.